- ASSISTANT PROFESSOR Genetics and Genomic Sciences
PhD, University of Southern California
BS, Fudan University
MS, University of Alabama at Birmingham
- Zhidong Tu works on developing systems approaches to study disease networks. By integrating large scale genomic and genetic information, he has worked on various problems including signaling pathway inference, drug target gene discovery, and biomarker identification. Dr. Tu received his PhD from Computational Biology program at University of Southern California. He then worked in the Genetics group at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc to study network of genes whose perturbation lead to type 2 diabetes. He later moved to Merck Boston site to work on cancer drug discovery, where the goal was to combine gene expression, sequence variation, drug response, drug-drug interaction to identify most effective medicine for cancer patients.
Please visit group webpages for more information.
Systems biology for disease network studyIntegrating and interpreting large scale genetic and genomic data turned out to be a promising approach towards understanding complex disease system. One large goal is to develop novel methods that stitch together various pieces of information to identify the network of genes whose perturbation by genetic variation would lead to disease phenotype. Multiple problems need better solutions:
-Better computational models for data-driven disease network discovery
-Mechanistic interpretation of the link between disease network and phenotype changes
-Systems strategy on disease network rectification and translational research
Wei Y, Peng S, Wu M, Sachidanandam R, Tu Z, Zhang S, Falce C, Sobie EA, Lebeche D, Zhao Y. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell research 2014 Mar; 24(3).
The Genotype-Tissue Expression (GTEx) project. Nature genetics 2013 Jun; 45(6).
Tu Z, Keller MP, Zhang C, Rabaglia ME, Greenawalt DM, Yang X, Wang IM, Dai H, Bruss MD, Lum PY, Zhou YP, Kemp DM, Kendziorski C, Yandell BS, Attie AD, Schadt EE, Zhu J. Integrative analysis of a cross-Loci regulation network identifies app as a gene regulating insulin secretion from pancreatic islets. PLoS genetics 2012 Dec; 8(12).
Zhu J, Sova P, Xu Q, Dombek KM, Xu EY, Vu H, Tu Z, Brem RB, Bumgarner RE, Schadt EE. Stitching together Multiple Data Dimensions Reveals Interacting Metabolomic and Transcriptomic Networks That Modulate Cell Regulation. PLoS biology 2012 Apr; 10(4).
Tu Z, Argmann C, Wong KK, Mitnaul LJ, Edwards S, Sach IC, Zhu J, Schadt EE. Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. Genome research 2009 Jun; 19(6).
Wang L, Tu Z, Sun F. A network-based integrative approach to prioritize reliable hits from multiple genome-wide RNAi screens in Drosophila. BMC genomics 2009; 10.
Tu Z, Wang L, Arbeitman MN, Chen T, Sun F. An integrative approach for causal gene identification and gene regulatory pathway inference. Bioinformatics (Oxford, England) 2006 Jul; 22(14).
Jiang R, Tu Z, Chen T, Sun F. Network motif identification in stochastic networks. Proceedings of the National Academy of Sciences of the United States of America 2006 Jun; 103(25).
Tu Z, Wang L, Xu M, Zhou X, Chen T, Sun F. Further understanding human disease genes by comparing with housekeeping genes and other genes. BMC genomics 2006; 7.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Tu during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Berg Pharma (Berg Biosystems)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Icahn Medical Institute Floor 3 Room L3-70F
1425 Madison Avenue
New York, NY 10029
Icahn Medical Institute Floor L3 Room 70-F
1425 Madison Avenue
New York, NY 10029